Terns Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
Terns Pharmaceuticals, a clinical-stage biopharmaceutical company focusing on serious diseases like NASH and obesity, will present at the 21st Annual Needham Virtual Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Terns Pharmaceuticals, a clinical-stage biopharmaceutical company focusing on serious diseases like NASH and obesity, will present at the 21st Annual Needham Virtual Healthcare Conference.
The presentation is scheduled for April 11, 2022, at 2:15 p.m. ET. Investors can access a live audio webcast via Terns' investor relations webpage, with a replay available for 30 days post-event.
Terns is developing a diverse pipeline of therapies, including an FXR agonist and a VAP-1 inhibitor.
Details
News Market Reaction – TERN
The recorded move for TERN in the trading session of this news was -1.69%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FOSTER CITY, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as non-alcoholic steatohepatitis (NASH) and obesity, today announced that management will be presenting at the 21st Annual Needham Virtual Healthcare Conference on Monday, April 11 at 2:15 p.m. ET.
A live audio webcast of the presentation will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcast will be archived on Terns’ website for 30 days following the presentation.
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as NASH and obesity. Terns’ pipeline includes three clinical stage development programs including an FXR agonist, a VAP-1 inhibitor and a THR-β agonist, and a preclinical small-molecule GLP-1 receptor agonist program. For more information, please visit: www.ternspharma.com.
Contacts for Terns
Investors
Justin Ng
investors@ternspharma.com
Media
Jenna Urban
Berry & Company Public Relations
media@ternspharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.